6NOU
An scFv derived from ixekizumab
Summary for 6NOU
Entry DOI | 10.2210/pdb6nou/pdb |
Related | 6NOV |
Descriptor | scFv derived from ixekizumab, GLYCEROL (3 entities in total) |
Functional Keywords | il17, il-17, ixekizumab, scfv, antibody, immune system |
Biological source | Homo sapiens |
Total number of polymer chains | 1 |
Total formula weight | 27987.24 |
Authors | Durbin, J.D.,Clawson, D.K.,Lu, F.,Tian, Y.,Lu, J.,Atwell, S. (deposition date: 2019-01-16, release date: 2019-06-19, Last modification date: 2019-08-14) |
Primary citation | Benschop, R.J.,Chow, C.K.,Tian, Y.,Nelson, J.,Barmettler, B.,Atwell, S.,Clawson, D.,Chai, Q.,Jones, B.,Fitchett, J.,Torgerson, S.,Ji, Y.,Bina, H.,Hu, N.,Ghanem, M.,Manetta, J.,Wroblewski, V.J.,Lu, J.,Allan, B.W. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. Mabs, 11:1175-1190, 2019 Cited by PubMed: 31181988DOI: 10.1080/19420862.2019.1624463 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.914 Å) |
Structure validation
Download full validation report